Cencora, Inc. (NYSE:COR) Position Trimmed by Metis Global Partners LLC

Metis Global Partners LLC reduced its holdings in Cencora, Inc. (NYSE:COR) by 5.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,211 shares of the company’s stock after selling 508 shares during the period. Metis Global Partners LLC’s holdings in Cencora were worth $1,845,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. JFS Wealth Advisors LLC boosted its stake in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares during the period. Householder Group Estate & Retirement Specialist LLC lifted its holdings in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co acquired a new position in Cencora during the 4th quarter valued at approximately $33,000. WASHINGTON TRUST Co grew its stake in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after buying an additional 46 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in Cencora in the third quarter worth $41,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Up 1.8 %

COR opened at $253.49 on Monday. The stock’s fifty day moving average is $241.71 and its 200-day moving average is $237.85. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The company has a market capitalization of $49.16 billion, a PE ratio of 36.06, a P/E/G ratio of 1.31 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of several recent research reports. Wells Fargo & Company lifted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Barclays increased their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Robert W. Baird lifted their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $277.90.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.